The acquisition strengthens Devyser’s customer offering within the aneuploidy segment and is expected to have a positive impact on Devyser’s gross profit and gross margin, it states.

“We are very pleased to complete the acquisition of Cybergene AB. The transaction strengthens our product offering within aneuploidy and male infertility, while at the same time improving our gross margins,” says Jan Wahlström, CEO, Devyser.

Cybergene

Cybergene develops and markets products in the fields of aneuploidy and male infertility, complementing Devyser’s existing product portfolio. The total purchase consideration amounts to appx. SEK 12.2 million and will be paid through newly issued shares in Devyser.

Cybergene was founded in 1995 and has demonstrated steady growth driven by a strong product offering and consistent market expansion. Devyser and Cybergene have been active in similar markets for many years, providing Devyser with in-depth knowledge of Cybergene’s products and their strong customer acceptance.